Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 396 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR The Galleri multi-cancer blood test: what you need to know September 13, 2021 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Mother Of 6 With ‘Open-Door Policy’ Packs 100 Lunches For Hungry... September 18, 2019 Load more HOT NEWS TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... Health of Gut Microbes May Affect Survival after Stem Cell Transplant
